Vertex Pharmaceuticals (VRTX) Net Cash Flow Growth (5y) (2014 - 2026)
Vertex Pharmaceuticals (VRTX) Net Cash Flow Growth (5y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.88% |
| Dec 31, 2025 | -26.29% |
| Sep 30, 2025 | -15.53% |
| Jun 30, 2025 | -27.92% |
| Mar 31, 2025 | -29.88% |
| Dec 31, 2024 | -16.77% |
| Sep 30, 2024 | 42.98% |
| Jun 30, 2024 | -68.10% |
| Mar 31, 2024 | -47.04% |
| Dec 31, 2023 | -45.27% |
| Sep 30, 2023 | 24.20% |
| Jun 30, 2023 | 40.62% |
| Mar 31, 2023 | -41.39% |
| Dec 31, 2022 | 35.83% |
| Sep 30, 2022 | 39.28% |
| Jun 30, 2022 | 36.52% |
| Mar 31, 2022 | 44.87% |
| Dec 31, 2021 | 4.79% |
| Sep 30, 2021 | 13.80% |
| Jun 30, 2021 | -125.84% |